Search Results

Now showing 1 - 4 of 4
Loading...
Thumbnail Image
Item

Cytocompatible, Injectable, and Electroconductive Soft Adhesives with Hybrid Covalent/Noncovalent Dynamic Network

2019, Xu, Yong, Patsis, Panagiotis A., Hauser, Sandra, Voigt, Dagmar, Rothe, Rebecca, Günther, Markus, Cui, Meiying, Yang, Xuegeng, Wieduwild, Robert, Eckert, Kerstin, Neinhuis, Christoph, Akbar, Teuku Fawzul, Minev, Ivan R., Pietzsch, Jens, Zhang, Yixin

Synthetic conductive biopolymers have gained increasing interest in tissue engineering, as they can provide a chemically defined electroconductive and biomimetic microenvironment for cells. In addition to low cytotoxicity and high biocompatibility, injectability and adhesiveness are important for many biomedical applications but have proven to be very challenging. Recent results show that fascinating material properties can be realized with a bioinspired hybrid network, especially through the synergy between irreversible covalent crosslinking and reversible noncovalent self-assembly. Herein, a polysaccharide-based conductive hydrogel crosslinked through noncovalent and reversible covalent reactions is reported. The hybrid material exhibits rheological properties associated with dynamic networks such as self-healing and stress relaxation. Moreover, through fine-tuning the network dynamics by varying covalent/noncovalent crosslinking content and incorporating electroconductive polymers, the resulting materials exhibit electroconductivity and reliable adhesive strength, at a similar range to that of clinically used fibrin glue. The conductive soft adhesives exhibit high cytocompatibility in 2D/3D cell cultures and can promote myogenic differentiation of myoblast cells. The heparin-containing electroconductive adhesive shows high biocompatibility in immunocompetent mice, both for topical application and as injectable materials. The materials could have utilities in many biomedical applications, especially in the area of cardiovascular diseases and wound dressing.

Loading...
Thumbnail Image
Item

Cryogel-supported stem cell factory for customized sustained release of bispecific antibodies for cancer immunotherapy

2017, Aliperta, Roberta, Welzel, Petra B., Bergmann, Ralf, Freudenberg, Uwe, Berndt, Nicole, Feldmann, Anja, Arndt, Claudia, Koristka, Stefanie, Stanzione, Marcello, Cartellieri, Marc, Ehninger, Armin, Ehninger, Gerhard, Werner, Carsten, Pietzsch, Jens, Steinbach, Jörg, Bornhäuser, Martin, Bachmann, Michael P.

Combining stem cells with biomaterial scaffolds provides a promising strategy for the development of drug delivery systems. Here we propose an innovative immunotherapeutic organoid by housing human mesenchymal stromal cells (MSCs), gene-modified for the secretion of an anti-CD33-anti-CD3 bispecific antibody (bsAb), in a small biocompatible star-shaped poly(ethylene glycol)-heparin cryogel scaffold as a transplantable and low invasive therapeutic machinery for the treatment of acute myeloid leukemia (AML). The macroporous biohybrid cryogel platform displays effectiveness in supporting proliferation and survival of bsAb-releasing-MSCs overtime in vitro and in vivo, avoiding cell loss and ensuring a constant release of sustained and detectable levels of bsAb capable of triggering T-cell-mediated anti-tumor responses and a rapid regression of CD33 + AML blasts. This therapeutic device results as a promising and safe alternative to the continuous administration of short-lived immunoagents and paves the way for effective bsAb-based therapeutic strategies for future tumor treatments.

Loading...
Thumbnail Image
Item

Screening Arrays of Laminin Peptides on Modified Cellulose for Promotion of Adhesion of Primary Endothelial and Neural Precursor Cells

2021, Wetzel, Richard, Hauser, Sandra, Lin, Weilin, Berg, Peggy, Werner, Carsten, Pietzsch, Jens, Kempermann, Gerd, Zhang, Yixin

Neural precursor cells (NPC) are primary cells intensively used in the context of research on adult neurogenesis and modeling of neuronal development in health and diseased states. Substrates that can facilitate NPC adhesion will be very useful for culturing these cells. Due to the presence of laminin in basal lamina as well as their involvement in differentiation, migration, and adhesion of many types of cells, surfaces modified with laminin-derived peptides are focused upon and compared with the widely used fibronectin-derived Arg-Gly-Asp (RGD) peptides. An array of 46 peptides is synthesized on cellulose paper (SPOT) to identify laminin-derived peptides that promote short-term adhesion of murine NPC and human primary endothelial cells. Various previously reported peptide sequences are re-evaluated in this work. Initial adhesion experiments show NPC preferred several laminin-derived peptides by up to 5-time higher cell numbers, compared to the well-known promiscuous integrin binding RGD peptide. Importantly, screening of cell adhesion has revealed a synergetic effect of filamentous matrix, peptide sequence, surface property, ligand density, and the dynamic process of NPC adhesion. © The Authors. Advanced Biology published by Wiley-VCH GmbH

Loading...
Thumbnail Image
Item

Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells

2017, Bachmann, Dominik, Aliperta, Roberta, Bergmann, Ralf, Feldmann, Anja, Koristka, Stefanie, Arndt, Claudia, Loff, Simon, Welzel, Petra, Albert, Susann, Kegler, Alexandra, Ehninger, Armin, Cartellieri, Marc, Ehninger, Gerhard, Bornhäuser, Martin, von Bonin, Malte, Werner, Carsten, Pietzsch, Jens, Steinbach, Jörg, Bachmann, Michael

Recent treatments of leukemias with T cells expressing chimeric antigen receptors (CARs) underline their impressive therapeutic potential but also their risk of severe side effects including cytokine release storms and tumor lysis syndrome. In case of cross-reactivities, CAR T cells may also attack healthy tissues. To overcome these limitations, we previously established a switchable CAR platform technology termed UniCAR. UniCARs are not directed against typical tumor-associated antigens (TAAs) but instead against a unique peptide epitope: Fusion of this peptide epitope to a recombinant antibody domain results in a target module (TM). TMs can cross-link UniCAR T cells with tumor cells and thereby lead to their destruction. So far, we constructed TMs with a short half-life. The fast turnover of such a TM allows to rapidly interrupt the treatment in case severe side effects occur. After elimination of most of the tumor cells, however, longer lasting TMs which have not to be applied via continous infusion would be more convenient for the patient. Here we describe and characterize a TM for retargeting UniCAR T cells to CD19 positive tumor cells. Moreover, we show that the TM can efficiently be produced in vivo from producer cells housed in a sponge-like biomimetic cryogel and, thereby, serving as an in vivo TM factory for an extended retargeting of UniCAR T cells to CD19 positive leukemic cells.